Chemical Structure : GLPG-0187
CAS No.: 1320346-97-1
Catalog No.: PC-42179Not For Human Use, Lab Use Only.
GLPG-0187 (GLPG0187) is a highly potent, broad spectrum integrin receptor antagonist with IC50 of 1-10 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $258 | In stock | |
10 mg | $428 | In stock | |
25 mg | Get quote | ||
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
GLPG-0187 (GLPG0187) is a highly potent, broad spectrum integrin receptor antagonist with IC50 of 1-10 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1.
GLPG-0187 significantly inhibits angiogenesis both in vivo and in vitro, osteoclastogenesis in vitro, and bone loss in vivo.
GLPG-0187 inhibits de novo formation and progression of bone and visceral metastases in prostate cancer and breast cancer mice models.
M.Wt | 595.713 | |
Formula | C29H37N7O5S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: 15 mg/mL |
|
Chemical Name/SMILES |
L-Alanine, 3-[[2,5-dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-4-pyrimidinyl]amino]-N-[(4-methoxyphenyl)sulfonyl]- |
1. Pujuguet P, et al. Eur J Cancer. 2011;47:S28. doi: 10.1016/S0959-8049(11)72695-8.
2. Cirkel GA, et al. Invest New Drugs. 2016 Apr;34(2):184-92.
3. van der Horst G, et al. Neoplasia. 2011 Jun;13(6):516-25.
4. Reeves KJ, et al. Int J Cancer. 2015 Apr 1;136(7):1731-40.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright